For primary hemophagocytic lymphohistiocytosis (HLH) with refractory. Sold as Gamifant. Every FDA application for this active ingredient. Orphan exclusivity to Jun 27, 2032
As of Nov 22, 2026, FDA lists 1 application for Emapalumab-lzsg (sold as Gamifant), first approved Nov 20, 2018, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Gamifant | Part B | $7.6M | +8% | 11 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantAcute Myeloid Leukemia, Graft Versus Host Disease · City of Hope Medical Center | Phase 1 | Recruiting | May 30, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA